Skip to main content

Table 1 Summary of Key Utility Parameter Estimates in Studies Cited in the Systematic Review

From: Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

Author QoL Source PF Utility PD Utility Pulmonary Disutility Diarrhea Disutility Endocrine Disutility
Ward CheckMate 141 EQ-5D QLQ-C30 QLQ-H&N 35 0.680 0.660 NR NR NR
Zagar CheckMate 141 NR NR −0.200 IO −0.207 IO −0.210 IO
Tringale CheckMate 141 0.517 0.280 NR NR NR
Goeree CheckMate 017 EQ-5D 0.789 0.674 -0.008 NR NR
Matter Walstra Literature 0.756 0.470 NR NR NR
Aguilar Literature 0.65 0.43 NR NR NR
Huang KEYNOTE 010 EQ-5D 0.761 0.687 −0.09 NR NR
Huang KEYNOTE 024 EQ-5D NR NR NR NR NR
Wan CheckMate 025 EQ-5D 0.848 0.68 NR NR NR
McCrea CheckMate 025 EQ-5D Re 0.895
SD 0.846
0.817 NR NR NR
Sarfaty CheckMate 025 FKSI-DRS 0.89 0.78 NR NR NR
Sarfaty NR NR NR NR NR NR
Barzey MDX010–20 SF-36 CR 0.88
SD 0.80
0.52 NR NR NR
Curl Literature and Expert Opinion Re 0.88
SD 0.80
0.52 NR −0.09 NR
Bohensky CA209066 EQ-5D 0.828 0.798 NR NR NR
Oh CheckMate 067 0.667 0.433 −0.159 IO − 0.116 IO − 0.115 IO
Wang KEYNOTE 006 EQ-5D 0.83–0.86 0.78 NR NR NR
Miguel KEYNOTE 006 EQ-5D 0.80 0.70 NR NR NR
Kohn Literature Re 0.88
SD first line therapy 0.80
0.52 −0.17 IO −0.17 IO − 0.17 IO
Meng CheckMate 066 EQ-5D 0.78–0.80 0.71–0.73 NR NR NR
  1. Note: Utility and disutility values used by the systematic review studies
  2. QoL quality of life, PF progression free, PD progressive disease, IO immune-oncology specific, NR not reported, Re response, SD stable disease, CR complete response